ArticleJournal of asthma and allergy2022
Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study.
Article in Journal of asthma and allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study).The European respiratory journal · 2024Trial
- Is Asthma Remission a New Achievable Goal? A Review of the Current Drug-Related Evidence and Predictors.Allergy · 2026Review
- Identification of predictive factors for clinical remission and comparison of 3 definitions in Japanese patients with severe asthma treated with biologics.The journal of allergy and clinical immunology. Global · 2026Article
- Benralizumab in Severe Eosinophilic Asthma: Toward Disease Control and Evolving Treatment Paradigms.Journal of inflammation research · 2026Review
- Impact of Overweight and Obesity in Severe Asthma Patients and Its Influence on Achieving Clinical Remission.Journal of asthma and allergy · 2026Article
- Exploring trends and predictors of long-term asthma remission.The World Allergy Organization journal · 2025Article
- Unlocking Asthma Remission: Key Insights From an Expert Roundtable Discussion.Respirology (Carlton, Vic.) · 2025Review
- Achieving remission in severe asthma.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability.The journal of allergy and clinical immunology. Global · 2025Article
- Effectiveness of anti-IL-5/5Rα biologics in severe asthma in real-world studies: a systematic review and meta-analysis.ERJ open research · 2025Article
- Clinical remission among severe asthmatics on monoclonal antibody therapy: real-world outcomes at 2 years.ERJ open research · 2024Article
- Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults.American journal of respiratory and critical care medicine · 2024Article
- Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study.Journal of clinical medicine · 2024Article
- Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: A Multicenter Prospective Observational Study.Journal of asthma and allergy · 2024Article
- Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps.Current allergy and asthma reports · 2024Review
- Clinical Asthma Remission Obtained with Biologics in Real Life: Patients' Prevalence and Characteristics.Journal of personalized medicine · 2023Article
- Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.Respiratory research · 2023Article
- Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study.International journal of molecular sciences · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Few studies on the long-term efficacy of benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, have been conducted for patients with severe eosinophilic asthma (SEA), especially regarding the improvement of pulmonary function and clinical remission in a real-world setting. Objective: To elucidate the long-term efficacy and clinical remission rate (CRR) in patients with SEA. Methods: From July 2018 to July 2022, 23 Japanese patients with SEA received benralizumab for two years or more at Jikei University Hospital. We retrospectively evaluated the patients' characteristics, biomarkers, number of exacerbations, pulmonary function, asthma symptoms, maintenance oral corticosteroid (OCS) dose and CRR. Results: The mean observation period was 38.3 (24-49) months. Among the 23 patients, 10 patients switched from mepolizumab to benralizumab. After administration of benralizumab, the forced expiratory volume in one second (FEV Conclusion: Long-term treatment with benralizumab significantly improved pulmonary function, alleviated asthma symptoms and decreased the number of exacerbations at two years in a real-world setting. The CRR may be associated with the BBC at baseline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.